We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Inv | LSE:HIO | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.75 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCOS
RNS Number : 2810E
Collagen Solutions PLC
03 November 2015
Collagen Solutions Plc
(the "Company" or the "Group")
Notice of Half Year Results
Analyst Briefing
The Board of Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, will announce their unaudited interim results for the six months ending 30 September 2015 on Tuesday, 1 December 2015.
A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Tuesday 1 December 2015.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email collagen@walbrookpr.com.
Enquiries:
Collagen Solutions Plc David Evans, Chairman Tel: 07740 084 452 Stewart White, CEO Tel: 0141 648 9100 Panmure Gordon Robert Naylor (Corporate Finance) Tel: 020 7886 2500 Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com Mike Wort Mob: 07900 608 002 Anna Dunphy Mob: 07876 741 001
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORFSLFMEFISELF
(END) Dow Jones Newswires
November 03, 2015 02:01 ET (07:01 GMT)
1 Year Healthcare Inv Chart |
1 Month Healthcare Inv Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions